within Pharmacolibrary.Drugs.ATC.B;

model B05CA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 16.666666666666668,
    adminDuration  = 600,
    adminMass      = 1.0,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>This drug group includes intravenous solutions containing combinations of electrolytes, such as sodium, potassium, calcium, magnesium, and chloride, used for correction of electrolyte imbalances, dehydration, and as vehicles for other drugs. These solutions are widely used for fluid and electrolyte replenishment and are approved and currently used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters for multi-electrolyte intravenous solutions in healthy adults. Since these are aqueous electrolyte solutions, distribution is almost immediate, and elimination depends on renal function and homeostatic mechanisms. Classic pharmacokinetic modeling parameters such as volume of distribution and clearance are generally not applicable in the traditional sense for electrolyte solutions, but basic estimated values can be provided.</p><h4>References</h4><ol><li><p>Mroszczak, EJ, et al., &amp; Massey, I (1990). Ketorolac tromethamine pharmacokinetics and metabolism after intravenous, intramuscular, and oral administration in humans and animals. <i>Pharmacotherapy</i> 10(6 ( Pt 2)) 33S–39S. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2082311/&quot;>https://pubmed.ncbi.nlm.nih.gov/2082311</a></p></li><li><p>Maguire, WF, et al., &amp; Appleman, LJ (2021). Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. <i>Cancer chemotherapy and pharmacology</i> 88(4) 643–654. DOI:<a href=&quot;https://doi.org/10.1007/s00280-021-04317-y&quot;>10.1007/s00280-021-04317-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34164713/&quot;>https://pubmed.ncbi.nlm.nih.gov/34164713</a></p></li><li><p>Tyler, T, et al., &amp; Stella, V (2022). Challenges in the Development of Intravenous Neurokinin-1 Receptor Antagonists: Results of a Safety and Pharmacokinetics Dose-Finding, Phase 1 Study of Intravenous Fosnetupitant. <i>Clinical pharmacology in drug development</i> 11(12) 1405–1418. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1183&quot;>10.1002/cpdd.1183</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36263927/&quot;>https://pubmed.ncbi.nlm.nih.gov/36263927</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B05CA10;
